drugset / Trial / NCT00326105

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

NCT00326105

Phase 3 Completed 450 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Timeline

Start
2006-04
Primary completion
Completion
2007-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 150 mg
Subject Quetiapine Small molecule 300 mg